La maladie de Parkinson au Canada (serveur d'exploration) - Exploration (Accueil)

Index « Keywords » - entrée « Parkinson Disease, Secondary (metabolism) »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Parkinson Disease, Secondary (immunology) < Parkinson Disease, Secondary (metabolism) < Parkinson Disease, Secondary (mortality)  Facettes :

List of bibliographic references indexed by Parkinson Disease, Secondary (metabolism)

Number of relevant bibliographic references: 32.
[0-20] [0 - 20][0 - 32][20-31][20-40]
Ident.Authors (with country if any)Title
000424 (2016) Marc Morissette [Canada] ; Nicolas Morin [Canada] ; Laurent Grégoire [Canada] ; Alex Rajput [Canada] ; Ali H. Rajput [Canada] ; Thérèse Di Paolo [Canada]Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
000508 (2015) Jackalina M. Van Kampen [Canada] ; David C. Baranowski [Canada] ; Harold A. Robertson [Canada] ; Christopher A. Shaw [Canada] ; Denis G. Kay [Canada]The Progressive BSSG Rat Model of Parkinson's: Recapitulating Multiple Key Features of the Human Disease
000985 (2014) Jackalina M. Van Kampen [Canada] ; David B. Baranowski [Canada] ; Christopher A. Shaw [Canada] ; Denis G. KayPanax ginseng is neuroprotective in a novel progressive model of Parkinson's disease.
000D90 (2013) Jovana Lubarda [Canada] ; Sarah E. Groleau ; Nancy Thomas ; Mark A. Ferro ; Ram K. Mishra ; Joseph P. GabrieleDysregulation of novel catecholamine-regulated protein 40 (CRP40) in Parkinson's disease patients.
001123 (2012) Laure Chagniel [Canada] ; Christine Robitaille ; Manon Lebel ; Michel CyrStriatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
001567 (2011) Melanie Bousquet [Canada] ; Karl Gue [Canada] ; Vincent Emond [Canada] ; Pierre Julien [États-Unis] ; Jing X. Kang [États-Unis] ; Francesca Cicchetti [Canada] ; Frederic Calon [Canada]Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease
001676 (2011) Maria Gabriela Sánchez [Canada] ; Erika Estrada-Camarena ; Nancy Bélanger ; Marc Morissette ; Thérèse Di PaoloEstradiol modulation of cortical, striatal and raphe nucleus 5-HT1A and 5-HT2A receptors of female hemiparkinsonian monkeys after long-term ovariectomy.
001743 (2011) Philippe Huot [Canada] ; Jonathan M. Brotchie5-HT(1A) receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: bridging the gap between serotonergic and glutamatergic mechanisms.
001A51 (2010) Qingjia Meng [Canada] ; Dirk W. Luchtman ; Bouchaib El Bahh ; Jeffrey A. Zidichouski ; Jun Yang ; Cai SongEthyl-eicosapentaenoate modulates changes in neurochemistry and brain lipids induced by parkinsonian neurotoxin 1-methyl-4-phenylpyridinium in mouse brain slices.
001A57 (2010) Bazoumana Ouattara [Canada] ; Fabrizio Gasparini ; Marc Morissette ; Laurent Grégoire ; Pershia Samadi ; Baltazar Gomez-Mancilla ; Thérèse Di PaoloEffect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys.
001E00 (2009) Mallika Somayajulu-Ni U [Canada] ; Jagdeep K. Sandhu [Canada] ; Jerome Cohen [Canada] ; Marianna Sikorska [Canada] ; Ts Sridhar [Canada, Inde] ; Anca Matei [Canada] ; Henryk Borowy-Borowski [Canada] ; Siyaram Pandey [Canada]Paraquat induces oxidative stress, neuronal loss in substantia nigra region and Parkinsonism in adult rats: Neuroprotection and amelioration of symptoms by water-soluble formulation of Coenzyme Q10
001E32 (2009) D. Litteljohn ; E. Mangano ; N. Shukla ; S. HayleyInterferon-gamma deficiency modifies the motor and co-morbid behavioral pathology and neurochemical changes provoked by the pesticide paraquat.
002440 (2007) Dianbo Qu [Canada] ; Juliet Rashidian ; Matthew P. Mount ; Hossein Aleyasin ; Mohammad Parsanejad ; Arman Lira ; Emdadul Haque ; Yi Zhang ; Steve Callaghan ; Mireille Daigle ; Maxime W C. Rousseaux ; Ruth S. Slack ; Paul R. Albert ; Inez Vincent ; John M. Woulfe ; David S. ParkRole of Cdk5-mediated phosphorylation of Prx2 in MPTP toxicity and Parkinson's disease.
002958 (2005) J E Nash [Canada] ; T H Johnston ; G L Collingridge ; C C Garner ; J M BrotchieSubcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia.
003545 (2000) Frédéric Calon ; Marc Morissette ; Martin Goulet ; Richard Grondin ; Pierre J. Blanchet ; Paul J. Bédard ; Thérèse Di Paolo125I-CGP 64213 Binding to GABAB Receptors in the Brain of Monkeys: Effect of MPTP and Dopaminomimetic Treatments
003848 (1998) E R Marcotte [Canada] ; A. Chugh ; R K Mishra ; R L JohnsonProtection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1)
003871 (1998) D J Doudet [Canada] ; G L Chan ; J E Holden ; E G Mcgeer ; T A Aigner ; R J Wyatt ; T J Ruth6-[18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys.
003A98 (1997) Marc Morissette [Canada] ; Martin Goulet [Canada] ; Jean-Jacques Soghomonian [Canada] ; Pierre J. Blanchet [Canada] ; Frédéric Calon [Canada] ; Paul J. Bédard [Canada] ; Thérèse Di Paolo [Canada]Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with l-DOPA therapy
003B15 (1997) Ian Q. Whishaw [Canada] ; Brenda L. K. Coles [Canada] ; Sergio M. Pellis [Canada] ; Elena I. Miklyaeva [Canada]Impairments and compensation in mouth and limb use in free feeding after unilateral dopamine depletions in a rat analog of human Parkinson's disease
003C91 (1996) A. Parent [Canada] ; M C Asselin ; P Y CôtéDopaminergic regulation of peptide gene expression in the striatum of normal and parkinsonian monkeys.
003C96 (1996) J P Doucet [Canada] ; Y. Nakabeppu ; P J Bedard ; B T Hope ; E J Nestler ; B J Jasmin ; J S Chen ; M J Iadarola ; M. St-Jean ; N. Wigle ; P. Blanchet ; R. Grondin ; G S RobertsonChronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Parkinson Disease, Secondary (metabolism)" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Parkinson Disease, Secondary (metabolism)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Parkinson Disease, Secondary (metabolism)
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022